secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001493152-25-026438
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics issues $2.09M unsecured note, net proceeds $1.5M, weekly $70K payments
--------------------------------------------------------------------------------

- Principal amount $2,093,340; net proceeds ~$1,500,000 after $587,340 OID and $6,000 fees.
- Weekly payments of $69,778 start December 12, 2025; full prepay by Jan 4, 2026 reduces balance by $286,140.
- Note is unsecured, no interest unless default; subsidiary Airway Integrated Management guarantees obligations.
- Proceeds for working capital and general corporate purposes; no placement agent used.
- Lender Avondale Capital is affiliate of Streeterville Capital (prior senior secured loan from June 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315225026438/0001493152-25-026438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315225026438/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-026438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer